Treatment of HCV in Patients with Renal Failure

Archives of Medical Research

Volumn 38, Issue 6, 2007, Pages 628-633

  Kalia, Harmit ^a   Lopez, Patricia M ^b   Martin, Paul ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Jaffe Food Allergy Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ERYTHROPOIETIN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ANEMIA; ANTIVIRAL THERAPY; BLOOD DONOR; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; GENOTYPE; GLOMERULONEPHRITIS; GRAFT SURVIVAL; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; PREVALENCE; REVIEW; SEROLOGY; SURVIVAL RATE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RIBAVIRIN;

EID: 34347220500     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.12.010     Document Type: Review

References (42)

1. Finelli L., Miller J.T., Tokars J.I., Alter M.J., and Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18 (2005) 52-61
2. Fissell R.B., Bragg-Gresham J.l., Woods J.D., Jadoul M., Gillespie B., Hedderwick S.A., et al. Patterns of HCV prevalence and seroconversion in hemodialysis units from three continents: the DOPPS Study. Kidney Int 65 (2004) 2335-2342
3. Jadoul M., Poignet J.L., Geddes C., Locatelli F., Medin C., Krajewska M., et al. The changing epidemiology of hepatitis C virus (HCV) in hemodialysis: European multicenter study. Nephrol Dial Transplant 19 (2004) 904-990
4. Gallego E., Lopez A., Perez J., Llamas F., Lorenzo I., Lopez E., et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Prac 104 (2006) c1-c6
5. Fabrizi F., Poordad F.F., and Martin P. Hepatitis C infection and the patient with endstage renal disease. Hepatology 36 (2002) 3-10
6. Marcelli D., Stannard D., Conte F., Held P.J., Locatelli F., and Port F.K. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 50 (1996) 1013-1018
7. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 354 (1999) 93-99
8. Stehman-Breen C.O., Emerson S., Gretch D., and Johnson R.J. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32 (1998) 629-634
9. Nakayama E., Akiba T., Marumo F., and Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 11 (2000) 1896-1902
10. Fabrizi F., Martin P., Dixit V., Bunnapradist S., and Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20 (2004) 1271-1277
11. Bloom R.D., Sayer G., Fa K., Constantinescu S., Abt P., and Reddy K.R. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 4 (2005) 139-144
12. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., and Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18 (2003) 1071-1081
13. Russo M.W., Goldsweig C.D., Jacobson I.M., and Brown R.S. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 98 (2003) 1610-1615
14. Rocha C.M., Perez R.M., Ferreira A.P., Carvalho-Filho R.J., Pace F.H., Silva I.S., et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 26 (2006) 305-310
15. Bruchfeld A., Stahle L., Andersson J., and Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 8 (2001) 287-292
16. Tan A.C., Brouwer J.T., Glue P., van Leusen R., Kauffmann R.H., Schalm S.W., et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16 (2001) 193-195
17. Bruchfeld A., Lindahl K., Reichard O., Carlsson T., and Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 13 (2006) 316-321
18. Annicchiarico B.E., and Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 20 (2004) 123-124
19. Sporea I., Sirli R., Golea O., Totolici C., Danila M., and Popescu A. Peg-interferon alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol 13 (2004) 99-102
20. Kokoglu O.F., Ucmak H., Hosoglu S., Centinkaya A., Kantarceken B., Buyukbese M.A., et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21 (2006) 575-580
21. Russo M.W., Ghalib R., Sigal S., and Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21 (2006) 437-443
22. Bruchfeld A., Lindahl K., Reichard O., Carlsson T., and Schvarcz R. Correspondence. Nephrol Dial Transplant 21 (2006) 1444-1446
23. Wolfe R.A., Ashby V.B., Milford E., Ojo A.O., Ettenger R.E., Agodoa L.Y., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341 (1999) 1725-1730
24. Casanovas-Taltavull T., Baliellas C., Benasco C., Serrano T.T., Casanova A., Perez J.L., et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 96 (2001) 1170
25. Huraib S., Iqbal A., Tanimu D., and Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 21 (2001) 435-440
26. Campistol J.M., Esforzado N., Martinez J., Rosello L., Veciana L., Modol J., et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 14 (1999) 2704-2709
27. Bunnapradist S., Fabrizi F., Vierling J., Martin R., Moudgil A., Kamil E., et al. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs 25 (2002) 1189-1193
28. Cruzado J.M., Casanovas-Taltavull T., Torres J., Baliellas C., Gil-Vernet S., and Grinyo J.M. Pretransplant interferon prevents hepatitis C associated glomerulonephritis in renal allografts by HCV RNA clearance. Am J Transplant 3 (2003) 357-360
29. Legendre C., Garrigue V., Le Bihan C., Mamzer-Bruneel M.F., Chaix M.L., Landais P., et al. Harmful long term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65 (1998) 667-670
30. Mathurin P., Mouquet C., Poynard T., Sylla C., Benalia H., Fretz C., et al. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 29 (1999) 257-263
31. Fabrizi F., Martin P., Dixit V., Bunnapradist M., and Dulai G. Hepatitis C virus antibody status and survival after renal transplant: meta-analysis of observational studies. Am J Transplant 5 (2005) 452-461
32. Kovarik J., Mayer G., Pokanta E., Schwarz M., Traindl O., Graf H., et al. Adverse effect of low dose prophylactic human recombinant leukocyte interferon-alpha in renal transplant recipients. Transplantation 45 (1988) 402-405
33. Rostaing L., Izopet J., Baron E., Duffaut M., Puel J., and Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59 (1995) 1426-1431
34. Shu K.H., Lan J.L., Wu M.J., Cheng C.H., Chen C.H., Lee W.C., et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 77 (2004) 1894-1896
35. Tang S., Cheng I.K., Leung V.K., Kuok U.I., Tang A.W., Wing Ho Y., et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 39 (2003) 875-878
36. Fontaine H., Vallet-Pichard A., Equi-Andrade C., Nalpas B., Verkarre V., Chaix M.L., et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 78 (2004) 853-857
37. Kamar N., Sandres-Saune K., Selves J., Ribes D., Cointault O., Durand D., et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 42 (2003) 184-192
38. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P.L., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330 (1994) 751-756
39. Johnson R.J., Gretch D.R., Couser W.G., Alpers C.E., Wilson J., Chung M., et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46 (1994) 1700-1704
40. Rossi P., Bertani T., Baio P., Caldara R., Luliri P., Tengattini F., et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 63 (2003) 2236-2241
41. Alric L., Plaisier E., Thebault S., Peron J.M., Rostaing L., Pourrat J., et al. Influence of antiviral therapy in HCV-associated cryoglobulinemia MPGN. Am J Kidney Dis 43 (2004) 617-623
42. Mazzaro C., Zanel F., Caizzi M., Donada C., Di Gennaro G., Maso L.D., et al. Treatment with pegylated interferon alpha 2b and ribavirin of HCV-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42 (2005) 632-636